



12 February 2018

Presage Biosciences Establishes Research Alliance with Codiak BioSciences Applying CIVO™ Intratumoral Microdosing to Exosome Therapeutics

Seattle, WA – February 12, 2018 – Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing, today announced that it entered into a research alliance with Codiak BioSciences. The collaboration will employ Presage’s CIVO™ intratumoral microdosing platform to assess novel exosome therapeutics.

“We are excited to be working with the scientific team at Codiak to investigate the biology of this new class of therapeutics. Exosomes have tremendous potential to therapeutically modulate historically difficult targets,” said Richard Klinghoffer PhD, Chief Scientific Officer of Presage. “The pairing of the CIVO™ platform and engineered exosomes is intended to accelerate early development and prioritize the most promising exosome agents for clinical advancement.”

Presage’s CIVO™ platform can assess the biology of tumor responses to perturbation by microdoses of multiple different agents and combinations. CIVO™ works by microinjecting and tracking up to eight columns of drug into a tumor. Unlike any traditional research approach, data can be obtained from multiple drugs across multiple tumor locations from a single tumor.

Financial terms of the agreement were not disclosed.

About Presage Biosciences

Presage Biosciences is an oncology company pioneering a new drug development approach to assess novel therapeutics and combinations directly in living tumors with its patented CIVO™ intratumoral microdosing platform. The CIVO device is intended to enable simultaneous assessment of responses to multiple drugs or drug combinations directly in a single tumor while still in a patient’s body. Presage also partners with oncology-focused pharmaceutical companies through strategic alliances to provide preclinical data to discover effective drug combinations. Presage is privately held and based in Seattle. For more information, visit www.presagebio.com.

#

Media Contact:

Kimberly Sottero
Presage Biosciences
206-995-8824
kimberly.sottero@presagebio.com